Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
National Institutes of Health · National Cancer Institute · +3 more institutions
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor heterogeneity and lack of biomarkers are thought to be some of the most difficult challenges driving therapeutic resistance and relapse. This review will summarize current therapy for TNBC, studies in treatment resistance and relapse, including data from recent single cell sequencing. We will discuss changes in both the transcriptome and epigenome of TNBC, and we will review mechanisms regulating the immune microenvironment. Lastly, we will provide new perspective in patient stratification, and treatment options targeting transcriptome…
Citation impact
- FWCI
- 24.55
- Percentile
- 100%
- References
- 127
Authors
4- JYJae Young So
National Institutes of Health, National Cancer Institute
- JEJoyce E. Ohm
Roswell Park Comprehensive Cancer Center, Cancer Genetics (United States)
- SLStan Lipkowitz
National Cancer Institute, National Institutes of Health, Center for Cancer Research
- YLYang LiCorresponding
National Institutes of Health, National Cancer Institute
Topics & keywords
- Triple-negative breast cancer
- Tumor microenvironment
- Epigenome
- Breast cancer
- Immune system
- Transcriptome
- Cancer research
- Medicine
- Good health and well-being